Amended Claims - Marked-Up Copy

1. A method of treating or ameliorating body wasting or cachexia in a patient with liver cirrhosis, chronic obstructive pulmonary disease, chronic *renal* failure, diabetes, rheumatoid arthritis in a patient the method comprising administering to the *patient* an effective amount of a compound that is able to reduce the production, *absorption and/or* the effect of an endotoxin (lipopolysaccharide; LPS).

2. (amended) A method ~~of~~ according to claim 1, further treating, preventing or ameliorating endotoxin-mediated immune activation in body wasting or cachexia in a patient with liver cirrhosis, chronic obstructive pulmonary disease, chromic renal failure, diabetes, rheumatoid arthritis the method comprising administering to the patient an effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin (lipopolysaccharide; LPS).

3. (amended) A method according to claim 1 ~~and 2~~ wherein the compound is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule.

4. (amended) A method according to claim 1 ~~to 3~~ wherein the compound is able to reduce *the* available endotoxin in the patient.

5. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is a bile acid.

6. (amended) A method according to claim 1 ~~to 4~~ wherein the bile acid is any one of ursodesoxycholic acid, chemodeoxycholic acid, dehydrocholic acid, cholic acid and deoxycholic acid.

7. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is LPS binding protein.

8. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is bactericidal/permeability increasing protein (BPI).

9. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is, a lipoprotein, for instance, low densitiy lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), apolipoprotein (a), a lipoprotein mixture.

10. (amended) A method according to claim 1 ~~to 4~~ wherein the treatment is a combination of a compound according claim 7 and claim 9.

Amended Claims - Marked-Up Copy

11. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is or an antibody capable of binding to endotoxin (lipopolysaccharide; LPS).

12. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is or an antibody capable of binding to endotoxin (lipopolysaccharide; LPS).

13. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is an antibody able to bind to the CD14 receptor.

14. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is a soluble CD 14 receptor.

15. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is a drug blocking effectively signaling through toll-like receptors, for instance toll-like receptor 4 and toll-like receptor 2.

16. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is colostrum of human, bovine, or other mamallian origin.

17. (amended) A method according to claim 1 ~~to 4~~ wherein the compound is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS).

18. (amended) A method according to claim 1 ~~to 4, and 17~~ wherein the compound is able to decrease the cytokine production by a cell in response to endotoxin (lipopolysaccharide; LPS).

19. (amended) A method according to claim 1~~, 2 and 17, and 18~~ wherein the compound is a compound named in claim 5 to 16.

20. (amended) A method according to ~~any one of the preceding claims~~ claim 1 wherein the compound is administered orally.

21. (amended) A method according to ~~any one of the preceding claims~~ claim 1 wherein the compound is administered intravenously.

22. (amended) A method according to ~~any one of the preceding claims~~ claim 1 wherein the compound is administered rectally.

~~23. The combined application of any method or use of any of the preceding claims in an individual patient.~~